June 16, 2026 — Niowave Inc., a manufacturer of medical radioisotopes, and Ratio Therapeutics Inc., a clinical-stage pharmaceutical company developing radiopharmaceuticals for cancer treatment, announced a supply agreement for Actinium-225. Under the agreement, Niowave will supply cGMP-grade Actinium-225 to support Ratio's development of targeted radiotherapeutics, providing reliable sourcing for ongoing clinical trial activities and future program advancement.
Actinium-225 is an alpha-emitting radioisotope with significant potential in targeted cancer therapies. When attached to targeting molecules, it delivers potent alpha radiation directly to cancer cells while minimizing damage to surrounding healthy tissue. As demand for targeted alpha therapies grows, establishing a reliable domestic supply of the isotope remains essential for clinical development and commercialization.
"Niowave is the leading partner for companies with radiopharmaceutical programs that require a reliable, scalable supply of Actinium-225, and we are pleased to be working with Ratio," said Matt Burba, President and Chief Commercial Officer of Niowave. "Our agreement demonstrates the growing importance of medical radioisotopes, especially Actinium-225, and their potential to bring new hope to patients."
John Babich, Ph.D., Chief Scientific Officer of Ratio Therapeutics, said: "Niowave's expertise and growing production capabilities make them an important partner as we continue advancing our radiopharmaceutical pipeline. This agreement supports our efforts to secure the Actinium-225 supply needed for ongoing clinical development while reinforcing our broader strategy of building the infrastructure and partnerships necessary to bring targeted alpha therapies to patients."
